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Factors Affecting Recurrence and Progression in
Superficial Bladder Tumours
K.H. Kurth, L. Denis, Ch. Bouffioux, R. Sylvester, F.M J . Debruyne, 
M. Pavone-Macaluso and W. Oosterlinck
Prognostic factors in superficial bladder tumours are highly correlated with each other. In this study, their relative 
importance is examined and grouping of patients in three different prognostic groups suggested. 576 patients 
(from EORTC protocols 30790 and 30782) were analysed. They have been followed from 3 months to 8.6 years 
with a median of 4 years. 76 patients developed an invasive tumour (>:T2); the shortest time to invasion was 12 
weeks, the longest was 6.6 years. Time from invasion to death ranged from 3 weeks to 4.4 years with a median of
2 years. Prognostic factors contributing to recurrence, invasion and survival were investigated: age, sex, size of 
largest tumour, number of tumours, T-category, G-grade, time from diagnosis (years), prior recurrence rate/year, 
site of involvement. The relative importance of these factors was measured by performing a multivariate analysis 
based on Cox’s proportional hazards regression model. Based on the most important prognostic factors and their 
association with invasion and death, an index was computed reflecting the risk of both invasion and death due to 
malignant disease, respectively. The index was used to assign patients to one of three prognostic groups. Three 
main factors determined patient’s prognosis: tumour size, G-grade and prior recurrence rate/year. The model 
coefficients for invasion were 0.51 (recurrence rate <l/year, 1-3/year, >3/year), 0.84 (grade 1, 2, 3), 0.48 (size 
<1.5, 1.5-3, >3 cm) and for death due to malignant disease 0.89 (recurrence rate), 0.73 (grade) and 0.44 (size), 
respectively. Risk groups are suggested based on the index. Additional treatment in patients with superficial 
transitional cell carcinoma of the bladder may be decided depending on the risk group to which the patient 
belongs.
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INTRODUCTION
P r o g n o stic  variables as well as patient characteristics influence 
the outcome of all forms of cancer. In superficial transitional cell 
carcinoma of the bladder (STCC), category Ta/Tl, prognostic 
factors may have a more important influence on further develop­
ment of the disease treated by transurethral resection than the 
choice of adjuvant chemotherapy or immunotherapy. Further­
more, treatments may have different effects in patients with 
different prognostic characteristics.
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PATIENTS AND METHODS
In 1979, the EORTC-GU group started two superficial bladder 
cancer trials based on almost identical protocols (30790, 30782). 
Data from these two trials (excluding control arm of 30790) 
were pooled to facilitate analysis of prognostic factors. Patients 
without follow-up for recurrence were excluded. The results 
from 576 patients, all of whom received intravesical chemo­
therapy, were analysed. No association was found between 
the adjuvant treatment group assigned and either recurrence, 
invasion, or survival. Thus, the drugs selected were equally 
effective [1,2]. Patients received either doxorubicin 50 mg 
(Farmitalia, Milano, Italy), cisplatin 50 mg, or thiotepa 50 mg 
(Lederle Laboratories, Pearl River, New York, U.S.A.), all 
dissolved in 50 ml saline, or epodyl 1.13 g (Zeneca, Cambridge, 
U.K.) dissolved in 100 ml waters weekly for 1 month and 
monthly for 1 year. If recurrences occurred during the first year, 
the patients received a further course of four times weekly 
treatment after transurethral resection with the same drug, 
but the total length of treatment did not exceed 12 months. 
Cystoscopy was performed every 3 months during year 1 of 
follow-up, every 4 months during year 2 and every 6 months
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Table 1. Patient characteristics
Patients % of patients
Coding Number % Recurrence Invasion Death MD
Overall 576 100 54 13 22 10
Age
(1) <60 154 27 57 9 8 5
(2) 61-79 379 66 52 15 26 12
(3) ^8 0 43 7 53 9 44 19
Sex
Female 97 17 52 9 15 4
Male 479 83 54 14 24 11
Size of largest tumour (cm)
(1) <1.5 347 61 53 9 18 7
(2) 1.5-3 133 23 55 19 29 15
(3) >3 94 16 55 22 29 14
Number of tumours
(1) —6 474 82 50 12 21 9
(2) > 7 102 18 69 18 29 17
T -category
( l )T a 310 54 54 9 21 9
(2)T1 266 46 53 18 24 11
G-category
(1)G1 236 44 47 6 16 4
(2) G2 247 46 59 17 26 14
(3) G3 56 10 61 30 25 16
Time from diagnosis (yrs)
(1) primary 219 38 43 14 25 8
(2) 1 or less 99 17 61 12 22 14
(3) 2 or 3 109 19 64 16 25 16
(4) >3 147 25 56 11 18 7
Prior recurrence rate/year
(1) primary 219 38 43 14 24 8
(2) <1 128 22 51 9 16 6
(3) 1-3 183 32 63 13 20 11
(4) >3 44 8 73 23 41 27
Trigone involvement
(1) No 492 85 52 11 21 9
(2) Yes 84 15 65 24 30 18
Right or left ureteral orifice
(1) No 422 73 56 13 23 11
(2) Yes 154 27 47 14 21 7
Right or left wall
(1) No 235 41 46 10 20 8
(2) Yes 341 59 59 15 24 12
Anterior wall
(1) No 504 87 53 13 21 10
(2) Yes 72 13 56 15 31 15
Posterior wall
(1) No 353 61 48 14 20 9
(2) Yes 223 39 62 12 26 13
Dome
(1) No 415 72 47 12 21 9
(2) Yes 161 28 70 15 25 14
Neck
(1) No 124 78 51 9 20 8
(2) Yes 452 22 65 21 33
*
18
First cystoscopy after entry
(1) Negative 480 83 44 10 21 8
(2) Positive 96 17 100 27 30 21
% positive cystoscopies after entry
(1) 30 or less 435 76 ---------------------------- 6 18 6
(2) >30 141 24 -------------------------- 37 37 25
MD5 death due to malignant disease.
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thereafter (provided there was no recurrence in the meantime). 
Patients were removed from the study when the first recurrence 
after 1 year of treatment or progression was observed.
Definition of end points 
Time to first recurrence is defined as the time from randomis­
ation to the time of first recurrence. Patients without recurrence 
were censored at the time they left the study (last cystoscopy).
The recurrence rate per year is defined as the number of 
follow-up cystoscopies at which a recurrence was seen, divided 
by the total number of months of follow-up. The result is then 
multiplied by 12. The recurrence rate takes into account the 
clinical course of patients during a longer interval and not only 
the time to first recurrence.
Time to invasion is defined as the time from randomisation 
until progression to stage T2 or worse. Patients without invasion 
were censored at the last available follow-up cystoscopy.
The duration of survival is defined as the time from entry into 
study until death. Patients still alive or lost to follow-up were 
censored at the last date they were known to be alive.
5 tatistical considerations
Curves estimating the time to first recurrence, invasion, and 
duration of survival among the various subgroups of patients 
were estimated using the Kaplan-Meier method [3] and com­
pared using the log-rank test [4]. Whenever a factor had ordered 
categories, a log-rank test for trend was carried out. A compari­
son of recurrence rates in the different levels of a given factor 
was performed using a non-parametric permutation test [5,6]. 
Finally, multivariate analyses based on Cox’s proportional haz­
ards regression model and Cox’s logistic regression model were 
used to measure the relative importance of the factors [7].
RESULTS
The 576 patients analysed were followed up from 3 months 
until 8.6 years, with a median of 4 years. Table 1 gives the 
distribution of patient characteristics for various factors.
At entry into the study, the patients were between 15 and 82 
years of age and 73% were older than 60 years of age. Thirty- 
eight per cent of the patients were newly diagnosed before 
entering into the trial. The others were patients with recurrent 
Ta or T1 tumours. Their diagnoses date from 9 weeks to 9.6 
years before entry, with a median of 2.4 years.
Table 2 shows how the patients’ characteristics are correlated 
with each other. For example, primary patients tend to have 
more and smaller tumours and no neck or dome involvement. A 
positive first control cystoscopy is significantly correlated with 
the size of largest tumour and the number of tumours, but also 
with the G-grade and site involvement. Neck involvement is 
significantly associated with dome or posterior wall involvement. 
A percentage of >30 positive cystoscopies (frequent recurrences) 
is significantly correlated with the number of tumours, G-grade, 
prior RR, site involvement and the result of the first control 
cystoscopy.
Time to first recurrence 
Tumours recurred in 54% of the 576 patients analysed (17% 
at first cystoscopy). Recurrence occurred at the earliest after 6 
weeks of follow-up and at the latest after 5 years. The median 
time to first recurrence was 94 weeks.
The univariate analysis identified the factors listed in Table 3 
as being associated with the time to first recurrence. These 
factors were highly correlated with each other (see Table 2). For
Table 2. Correlation between factors
Sex 0
*
Size of largest tumour 0 0 *
Number of tumours 0 0 0 *
T-category 0 + + 0 *
G-grade + 0 + 0 + *
Primary/recurrent* 0 0 — + 0 0 *
Time from diagnosisf + 0 0 0 0 0 * afe
Prior recurrence ratef 0 0 0 + 0 0 * — *
Trigone 0 0 0 + 0 0 + 0 0 *
Ureteral orifice 0 0 0 0 0 *—— 0 0 0 *
Wall 0 — + 0 0 0 0 0 0 — *
Anterior wall 0 0 + 0 0 + 0 0 + 0 0 *
Posterior wall 0 0 — + 0 0 + 0 0 -1- — 0 + *
Dome 0 0 — + — 0 + + 0 + 0 0 + + *
Neck 0 0 + + 0 + + 0 0 + 0 0 0 + +
First cystoscopy 0 0 + j^iwi 0 + + — + 0 0 + + + +
% positive cystoscopies 0 0 0 + 0 + + — + + 0 0 + +
*
A$S S N T G P T P T U W A P D N F %
+ , significant positive correlation (P <  0.05); - ,  significant negative 
correlation (P < 0.05); 0, no correlation.
*Code: 1 = primary; 2 = recurrent; f  In order to compute the 
correlations with these factors primary patients have been excluded; $ 
Letters correspond to initial letters of coding characteristics used in 
Table 1.
Table 3. Univariate analysis for time to first recurrence
Prognostic factor P value
Number of tumours <0.0001
G-grade 0.0016
Prior recurrence rate <0.0001
Time from diagnosis <0.0001
Involvement of
trigone 0.0007
wall 0.0022
posterior wall <0.0001
dome <0.0001
neck 0.0001
instance, the number of tumours was positively correlated with 
the prior recurrence rate and site involvement and negatively 
correlated with tumour size. Also, neck and trigone involvement 
tended to be associated with either wall or dome involvement.
The association of these factors with the time to first recur­
rence was assessed by Cox’s model as given in Table 4.
On reanalysing the data by ignoring sites of involvement, the 
number of tumours becomes a more important factor. The 
importance of involvement can be explained by the fact that the 
site brings a refinement to the number of tumours variable.
Recurrence rate per year 
The endpoint recurrence rate per year was likewise analysed 
in a multivariate model using logistic regression. Again, the 
prior recurrence rate, G-grade, and number of tumours were the 
most important prognostic factors (P < 0.0001).
As a further endpoint, the recurrence rate starting after the 
first follow-up cystoscopy after 3 months (zero-point first follow- 
up cystoscopy) was used. Among the 576 patients analysed, 96
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Table 4. Multivariate analysis for lime to first recurrence
Prognostic factors Estimated coefficient P value
Involvements included
Prior recurrence rate 0.357 <0.0001
T  umour size 0.191 0.03
G-grade 0.297 0.001
Involvement of
lateral wall 0.377 0.002
posterior wall 0.273 0.02
dome 0.406 0.001
Involvements excluded
Prior recurrence rate 0.387 <0.0001
Tum our size 0.204 0.02
G-grade 0.282 0.002
Num ber of tumours 0.270 0.07
Variables are coded as in Table 1.
Table 5. Multivariate analysis of recurrence rate per year taking the
first follow-up cystoscopy at 3 months as zero point
Prognostic factor P value
Recurrence at 3 months (yin) <0.001
Prior recurrence rate <0.001
Num ber of tumours at entry <0,001
G-category 0.01
T-category* NS
NS, not significant.
* Based on local pathology.
(17%) already had a recurrent tumour at the first cystoscopy. 
The most important prognostic factor for the long-term recur­
rence rate was by far the presence or absence of recurrence at 3 
months (Table 5).
Whereas 53% of the patients without recurrence at 3 months 
remained free of further recurrences, only 17% with recurrence 
at 3 months experienced no further recurrences during follow- 
up (Table 6).
Time to invasion
Out of 576 patients, 76 progressed to T2 or worse, 43 (57%) 
did so while on treatment. The shortest time to muscle invasion 
was 12 weeks, and the longest was 6.6 years (Figure 1). Although 
muscle invasion was observed only in a few patients, one can 
expect to identify prognostic factors for this endpoint. In fact, 
the loss of power due to the small number of patients with 
invasion was balanced by the strong association between invasion 
and the prognostic factors. As for the dme to first recurrence
Table 6, Recurrence in relation to presence o f tumour at the first
follow-up cystoscopy 3 months after entry into study
Recurrence N um ber of future recurrences
at 3 months 0 1 2 > 3  Total
No 235 (53%) 165 (37%) 42 (9%) 6 (1%) 448
Yes 12(17%) 39(55%) 14(20%) 6(8%) 71
Total 247 204 56 12 519
Time to invasion-percentage cystoscopies with tumour
EORTC-GU 
30890-30782 (Ta-Tl bladder cancer) « = 576
Years
Num ber o f patients at risk at the corresponding times:
435 405 343 248 225 162 73 28 9 0 LE 30% 
141 97 69 52 40 28 9 2 0 0 GT 30%
Figure 1. The risk of developing muscle invasive disease (sT 2 ) in 
patients with superficial bladder tumour, category Ta/TL Taking 
more than 30% positive cystoscopies as cut-off point, the difference
is highly significant (P <  0.0001).
and recurrence at 3 months, the univariate analysis identified 
tumour size, prior recurrence rate, G-grade, and involvement of 
trigone, wall or neck, as being important prognostic factors. The 
T-category and age were also factors related to invasion. Finally, 
recurrence at the first cystoscopy was highly correlated with 
invasion, Surprisingly, there was a negative association of pos­
terior wall involvement with invasion and the number of tumours 
could not replace site involvement. The probability of 
developing muscle invasive disease was higher in patients with 
greater than 30% of positive cystoscopies (Figure 1),
The multivariate analysis confirmed that all these variables 
except T-category (correlated with tumour size and G-grade), 
and wall or neck involvement were associated with future 
invasion. The oldest patients had a risk of invasion similar to 
patients younger than 60 years of age. Results of the multivariate 
analysis are shown in Table 7.
S  urvival
Out of 576 patients, 129 (22%) died of various causes. Death 
occurred between 18 weeks and 8.2 years after entry into the 
study. The survival at 5 years was 75%. According to the 
univariate analysis, patients with the poorest prognosis tended 
to have a high recurrence rate at entry, numerous tumours, high 
G-grade, and involvement of the anterior wall, posterior wall or 
neck. Moreover, they were often old, male, and had already had
Table 7. Multivariate analysis for time to invasion (n = 535)
Factor Estimated coefficient P  value
First cystoscopy 1.082 <0.0001
G-grade 0.867 <0,0001
Prior recurrence rate 0.517 0.005
Posterior wall involvement -0 .6 4 5 0.01
Trigone involvement 0.533 0.05
Tum our size 0.396 0.01
Sex 0.752 0.03
Coded as in Table 1. 4
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Table 8. Multivariate analysis for survival: all causes of death
(n = 535)
Factor Estimated coefficient P value
Involvement excluded
Age 1.097 0.001
Sex 0.707 0.01
Prior recurrence rate 0.482 0.001
Tumour size 0.312 0.009
Table 9. Multivariate analysis of time to death due to malignant
disease (n =  535)
Factor Estimated coefficient P value
Involvement excluded
Age 1.061 <0.0001
Sex 1.423 0.006
Prior recurrence rate 1.053 <0.0001
G-grade 0.755 0.0005
Tumour size 0.414 0.02
a positive cystoscopy 3 months after entry. The multivariate 
analysis, which studies the possible correlation between these 
factors, identified (involvement excluded) age, sex, prior RR 
and tumour size and G-grade, as being associated with survival 
(Table 8).
An analysis of disease-related deaths was also carried out. 53 
patients (10%) died of malignant disease. Their time to death 
ranged from 23 weeks to 7 years. The factors most associated 
with death of malignant disease were (site of involvement 
excluded) age, sex, prior recurrence rate, G-grade and tumour 
size (Table 9).
Figure 2 shows the survival curves for G-grade. For the 76 
patients with invasion, the time from invasion to death ranged
Time to death from malignant disease-grade
EORTC-GU
30790-30782 (Ta-Tl bladder cancer) n a 539
1.0
0.9
0.8
0.7
0.6
~ 0 5X)cd
*g 0-4
£  0.3 
0.2 
0.1
" 1
P
P
Total Fail G grade
-  236 9 Gl
-  247 35 G2 
- - 5 6  9 G3
= 0.001 (Log-rank overall) 
= 0.001 (Log-rank irend)
0 1 82 3 4 5 6 7
Years
Number of patients at risk at the corresponding times:
236 221 187 155 123 92 41 16 5 0 G1 
247 227 197 160 126 97 38 12 6 0 G2 
56 47 44 36 30 15 7 2 0 0 G3
Figure 2. Time to death from malignant disease curves show an 
increased probability of death with an increased undifferentiation of
the tumour (P <  Û.001).
Time to invasion-risk groups
30790-30782 (Ta-Tl bladder cancer)
EORTC-GU
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1.0
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0 i 7 82 3 4 5 6
Years
Number of patients at risk at the corresponding times: 
281 257 207 174 139 106 47 17 5 0 1 
218 183 153 121 98 65 27 8 4 0 2 
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Time to death from malignant disease-risk groups
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1
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0.001 (Log-rank overall) 
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Number of patients at risk at the corresponding times:
281 263 222 184 148 115 53 19 7 0 1 
218 198 175 140 114 79 30 10 4 0 2 
36 30 29 25 15 8 3 1 0 0 3
Figure 3. The distribution of (a) time to invasion and (b) time to 
death from malignant disease in each of the three risk groups.
from 3 weeks to 4.4 years, with a median of 2 years. To determine 
to what degree invasion was associated with survival, a variable 
representing invasion was included and updated at 1, 2 and 3 
years using the best model for survival. Invasion then became, 
with age, the most significant factor (P < 0.0001).
Time to invasion and percentage of positive cystoscopies (less 
or more than 30%) were both clearly correlated with survival, 
and hence can be used as surrogate endpoints. It is advisable 
to use the recurrence rate, however. When comparing two 
treatments, the number of patients with invasion during adju­
vant treatment is so small (7%) that one would need a large
number of patients to detect improvement in the time to 
invasion.
Risk groups for progression (> 72) and death due to malignant 
disease
Three main factors determine the patient’s prognosis: tumour 
size, G-grade and prior recurrence rate (grouping primary with 
a recurrence rate of less than one in a year). Based on these three
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Table 10* Risk index for patients in various subgroups
Tumour size Primary, RR <1 1-3 > 3
(G-grade) <1.5 1.5-3 > 3 <1.5 1.5-3 >3 <1.5 1.5-3 > 3
G1 I 1 1 1 2 2 2 2 3
0 0.48 0.97 0.51 1.0 1.5 1.0 1.5 2.0
0 0.44 0.87 0.89 1.3 1.8 1.8 2.2 2.7
77 36 26 71 6 4 12 2 0
G2 1 2 2 2 2 3 3 3 3
0.84 1.3 L8 1.4 1.8 2.3 1.9 2.4 2.8
0.73 1.2 1.6 1.6 2.1 2.5 2.5 3.0 3.4
71 38 38 53 19 3 13 9 1
G3 2 2 2 2 3 3 3 3 3
1.7 2.2 2.7 2.2 2.7 3.2 2,7 3.2 3.7
1.5 1.9 2.3 2.4 2.8 3.3 3.3 3.7 4.1
12 10 15 9 4 2 2 2 0
Each cell gives the risk group, the risk index pertaining to invasion and death from malignant disease as well as the num ber of patients.
RR, recurrence rate per year.
Risk index, odds ratio estimated from the Cox model including only three factors: Tumour Size (TS), G-grade (G) and RR.
The estimated Cox models are: for invasion: 0.51 RR +  0.84 G + 0.48 TS; for death: 0.89 RR + 0.73 G + 0.44 TS. The bold numbers in the table 
refer to the risk group: (1) 254 patients; (2) 218 patients; (3) 36 patients.
factors and their association with invasion and death due to 
malignant disease, an index was computed reflecting the risk of 
early invasion and death due to malignant disease (Table 10).
Table 11 shows the observed rate of tumour progression and 
death due to malignant disease according to the risk group as 
defined in Table 10. Figure 3a,b shows the distribution of time 
to invasion and death from malignant disease in each risk group.
DISCUSSION
Superficial bladder cancer comprises a spectrum of disease 
processes. Identification of prognostic variables predictive of 
recurrence and muscle invasion would identify which patients 
require adjuvant therapy after TUR (transurethral resection) or 
are candidates for additional surgery and, conversely, for which 
patients the potential toxic effects and cost of adjuvant chemo­
therapy could be spared.
In the present study, previous recurrence rate, tumour size 
and grade of the tumour when tested with other prognostic 
factors (as listed in Table 1) in a multivariate model were the 
most powerful predictors of either recurrence, muscle invasive 
disease or death due to malignant disease. Patients with a 
recurrent tumour at the first 3 month cystoscopy study did 
particularly poorly and had the highest chance of developing 
new recurrences and/or progressing to >T2. This confirms an 
earlier observation, reported by Parmar and colleagues for 
the British Medical Research Council subgroup on superficial 
bladder cancer [8]. Surprisingly the T-category (Ta/Tl) did not
Table 11. Tumour progression and death due to malignant disease
(DMD) by risk group
Group No. of patients Progression (%) DM D (%)
1 281 20 (7.1) 12(4.3)
2 218 38(17.4) 28(12.8)
3 36 15(41.6) 13(36.1)
Total 535 73(13.6) 53(9.9)
add to the prognostic information and did not improve the 
separation between different groups. T-category in the present 
study was based on local pathology. Overestimation of the T- 
category may contribute to the lack of predictive value of this 
prognostic factor. Oosterlinck and associates reported that out 
of 96 patients with a Tl-tumour as diagnosed by the local 
pathologist, only 41.6% were confirmed by the review pathol­
ogist, whereas 5.1% staged Ta were understaged and had a T1 
lesion [9]. Similar observations were made by others [1, 8].
Thus, pathologists most likely upstage the pathological diag­
nosis. On the other hand, a higher percentage of pathologists 
seem to agree on the grade of the tumour. In the report by 
Oosterlinck and associates, agreement between local and review 
pathology is reported in 61.8%, a higher degree of undifferen­
tiation by the review pathologist was seen in only 18% [9].
Size and previous recurrence rate are easy to calculate, and, 
therefore the three most powerful predictors of either recurrence 
or invasive disease are available in daily practice and allow 
assignment of a given patient to one of the three risk groups 
(Table 10). Obviously, more aggressive treatment (e.g. cystec­
tomy and urinary diversion) should be considered only for those 
patients with superficial bladder tumour who failed conservative 
treatment (transurethral resection followed by either chemo- or 
immunotherapy) and who are assigned to risk group 3 (Table 
10). This group is small in the present study (6.7%), but of a 
similar size (6 to 9%) as the poor risk group for recurrence and 
survival computed in a different way by Parmar and colleagues 
[8]. Patients possessing the criteria for the best profile might be 
spared adjuvant chemo- or immunotherapy until a worsening of 
one of these prognostic factors occurs.
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